Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
honubicistmut-L
- Development stage
- Phase 2
- Lead developer
- Lisata Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Honubicistmut-L (CLBS12) is an autologous cell therapy consisting of CD34+ hematopoietic stem cells isolated from a patient's own peripheral blood following mobilization with granulocyte-colony stimulating factor (G-CSF). Developed by Caladrius Biosciences (now Lisata Therapeutics), this therapy is designed for its regenerative potential in treating ischemic conditions, primarily critical limb ischemia (CLI) and Buerger's disease. The proposed mechanism of action is the promotion of new blood vessel formation (angiogenesis) in tissues with poor blood supply. The CD34+ cells are administered via intramuscular injection directly into the ischemic limb to improve perfusion and reduce the risk of complications like amputation. The therapy received SAKIGAKE designation in Japan, making it eligible for early conditional approval based on Phase 2 clinical data.
- Brand names
- HONEDRA
- Other names
- CD34+ cell therapyautologous CD34+ hematopoietic stem cells
Beyond the preview
Go deeper on honubicistmut-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on honubicistmut-L.